Locations:
Search IconSearch

Approaches to Treatment of Chest Wall Sarcomas

Advanced radiotherapy in a rare soft-tissue sarcoma

650x450_Chest-Wall-Sarcoma

A patient in whom radiation both cured breast cancer and caused heart disease — necessitating a transplant — presents 25 years after initial radiotherapy with a mass on her left chest wall above her transplanted heart.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“When we diagnose patients like this with chest wall sarcomas, they are often surprised to hear that radiotherapy is part of the answer, though initial radiation may have contributed to the current cancer’s development,” says Chirag Shah, MD, Director of Clinical Research, Radiation Oncology, Cleveland Clinic. “With advanced techniques, we can often treat these rare cancers.”

Primary soft tissue sarcomas (STS) of the chest wall are rare, accounting for less than 5% of all thoracic malignancies, and can be difficult to treat. “We see them most often in women who have had radiation for breast cancer or for Hodgkin’s lymphoma,” says Dale Shepard, MD, PhD, Co-Director of Cleveland Clinic Cancer Center’s Rare Cancer and Blood Disease Program. “But we also see patients with no history of cancer or radiation therapy.”

Breast cancer and Hodgkin’s survivors who develop radiation-induced chest wall sarcomas are often told that they have few options because they cannot have radiation again. Cleveland Clinic’s Rare Cancer and Blood Disease Program, however, is designed to help such patients by giving them the collective expertise of dozens of specialists who study, diagnose and treat uncommon diseases on a regular basis.

A recent review of 192 patients with chest wall sarcomas found that five and 10-year survival rates were 73% and 61%, respectively, with a median survival of 14 years. Symptoms can include a mass or pain or nothing at all, with the tumor discovered upon routine chest radiograph. Distinguishing from Ewing sarcoma and osteosarcoma with core needle biopsy is critical given the different treatment approaches.

Advertisement

In the case of radiation-induced chest wall sarcomas, the malignancy may not develop until 20 to 25 years after the original cancer was treated. “It can even happen after a mastectomy,” says Dr. Shah, “but it often happens deep in the chest wall so sometimes it’s not something that can be seen by the naked eye or felt on a physical exam early on.”

Radiotherapy approaches

In the case of this breast cancer survivor with a heart transplant, physicians were able to give her targeted radiation and then remove the mass with negative margins.

“In this patient, and in many other patients we treat with chest wall sarcoma, we used a variety of techniques, including brachytherapy,” says Dr. Shah. Very few centers in the U.S. offer brachytherapy for chest wall sarcomas, and Dr. Shah and Jacob Scott, MD, DPhil, were recently co-authors on national guidelines regarding this technique.

“We also incorporate various cardiac- and lung-sparing techniques, including the use of deep inspiratory breath hold during treatment planning, an active breathing control system during daily treatment and heart blocks.” The team is preparing data for publication showing that cardiac doses at Cleveland Clinic are lower than the national standard by more than 50 percent.

“If you exclude the most complicated cases treating targets near the heart, the average is closer to a 75 percent reduction,” says Dr. Shah. “We’re really proud of what we’ve been able to achieve for our patients using a combination of cardiac-sparing techniques.”

Team approach

Because chest wall sarcomas are so challenging to treat, physicians with Cleveland Clinic’s Rare Cancer and Blood Disease Program use an interdisciplinary approach that involves thoracic surgery, plastic surgery, medical oncology and radiation oncology.

Advertisement

“Before we even start treatment, we meet as a group and plan it out,” says Dr. Shah. “Everything has to be coordinated very carefully. Before we offer treatment, we’ll discuss the case, review the imaging and talk about how to best sequence things. Most of the time that’s radiation followed by surgery but sometimes it’s actually surgery followed by radiation. It’s a discussion of what’s best for the patient and what surgical and reconstructive approach will be.”

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad